AstraZeneca gets FDA priority review for experimental breast cancer drug
October 17, 2019 at 02:29 AM EDT
Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of next year.
